Brian G. Till

TL;DR: Several chemotherapeutic agents used in conventional cancer chemotherapy have been found to reduce MDSC numbers in tumor tissues as well as in the peripheral lymphoid organs, and combining these agents with immunotherapy improved survival of tumor-bearing hosts.

TL;DR: Biological characteristics of γδ T cells that are distinct from those of αβ T cells are highlighted, including homing to epithelial and mucosal tissues and unique functions such as direct antigen recognition, lack of alloreactivity, and ability to present antigens that make them promising for use in cellular therapy against several types of solid tumors.

TL;DR: The identification of two modifiable pre-treatment factors independently associated with better outcomes after CART2 suggests strategies to improve in vivoCAR T-cell kinetics and responses after repeat CAR T- cell infusions, and has implications for the design of trials of novel CART-cell products after failure of prior CAR T -cell immunotherapies.

TL;DR: An intensive induction regimen before HDT and ASCT was not associated with improved survival after adjusting for differences in MIPI scores at diagnosis, and this work concluded that high-dose therapy and autologous stem-cell transplantation should be considered as separate treatments.

TL;DR: The T Cell Immunotherapy: Optimizing T-cell trial design workshop as discussed by the authors was a workshop sponsored by the National Institutes of Health's Office of Biotechnology Activities (OBA), which brought together researchers to discuss the scientific advances and share new data on key trial design issues.